Document is current
Any future updates will be listed below
-
Authors
Simon, Linda
Vucinic, Vladan https://orcid.org/0000-0002-8398-285X
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
Schubert, Maria-Luisa
Aydilek, Enver https://orcid.org/0000-0003-1418-2725
Wagner-Drouet, Eva-Maria https://orcid.org/0000-0002-0728-2253
Penack, Olaf https://orcid.org/0000-0003-4876-802X
von Bonin, Malte
von Tresckow, Bastian
Teichert, Marcel
Marks, Reinhard
Pott, Christiane
Fehr, Martin
Leng, Corinna
Schroers, Roland https://orcid.org/0000-0003-2744-5491
Koenecke, Christian
Duell, Johannes
Stilgenbauer, Stephan https://orcid.org/0000-0002-6830-9296
Mueller, Fabian https://orcid.org/0000-0001-5487-5839
Hecker, Judith S.
Brunnberg, Uta
Kroeger, Nicolaus
Kronfeld, Kai
Theobald, Matthias
Ohler, Anke
Schmidtmann, Irene https://orcid.org/0000-0001-8743-6752
Hess, Georg https://orcid.org/0000-0002-9282-5688
Dreger, Peter https://orcid.org/0000-0002-7429-8570
- License Information
-
More Information
Article History
Received: 27 July 2025
Revised: 19 November 2025
Accepted: 12 December 2025
First Online: 16 January 2026
Competing interests
: LS received honoraria or travel support from AstraZeneca, Incyte. VV received honoraria from Gilead/Kitę, Novartis, BMS Celgene, Janssen, KR received research funding from Kite/Gilead, is an consultant and received honoraria and travel support from Novartis, BMS/Celgene, Pierre-Fabre, CSL Behring. MLS reports honoraria and travel funds from Kite/Gilead, Takeda, Janssen, and Sobi. EA received honoraria from AstraZeneca, Gilead, Janssen, Lilly. MT is an advisor or consultant for Janssen-Cilag, has received honoraria from BMS/Celgene, Janssen-Cilag, BPM Pharma, Medothic GmbH. MF has received remuneration and financial support in form of travel support (Abbvie, Janssen J&J Innovative Medicine, Takeda, Kite/Gilead), consulting and advisory fees (E.Lilly, Incyte, Kite/Gilead). CL received honoraria for attending symposia and travel support from Pierre Fabre, BristolMyersSquibb, Janssen. CK received honoraria from Janssen, BMS, Novartis, Kite/Gilead. JH received honoraria for consulting and travel support from J&J, Servier, Kite/Gilead, Novartis, BMS/Celgene, Iovance, Imatics. GH has received research support or contracts from Celgene, Kite, a Gilead Company, Incyte, Janssen, Morphosys, Pfizer, and Roche; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, ADC, AstraZeneca, Genmab, Kite/Gilead, Incyte, Janssen, Morphosys, Novartis, Roche, and Takeda; has received support for attending meetings and/or travel from Kite/Gilead and Janssen; and has participated in on a Data Safety Monitoring Board or Advisory Board for Miltenyie. PD received consultancy from AbbVie, AstraZeneca, Bluebird Bio, Gilead, Janssen, Novartis, Riemser, and Roche; received speaker’s bureau fees from AbbVie, AstraZeneca, Gilead, Novartis, Riemser, and Roche; and received research support from Riemser. The remaining authors declare no competing financial interests.
: The study is part of the EMCL-R and DRST which was approved by the Ethical Committee of Rhineland-Palatinate (Ref. Nr. 2018-13856). Written informed consent in accordance with the European data protection regulations and the Declaration of Helsinki was obtained from all participants alive. The registries allowed for inclusion of deceased patients without prior written informed consent.
